Background: HIV-2 is a new retrovirus which may produce AIDS and has been mainly described in individuals from West Africa. More than 400 cases have been reported in France and Portugal while in Spain very few cases of HIV-2 infection have been reported with few studies having been made concerning the prevalence of the disease. This multicentric study analyzes the prevalence of HIV-2 infection in subjects of different risk groups in Spain and evaluates the diagnostic efficacy of different methodologies.
Methods: The presence of HIV-2 antibodies was analyzed in 902 serum samples of high risk individuals collected in 1990 from: 386 drug addicts, 246 not drug addict prostitutes, 184 West Africans and 86 homo/bisexual individuals. These samples were from Barcelona, Sevilla, and Malaga. The detection of antibodies was carried out by enzymatic immunoanalysis (EIA), Western blot (WB) and an enzymoimmuno-dot (EID) designed with synthetic peptides.
Results: Positive serology only for HIV-2 was detected in 7 samples from African immigrants. Two drug addicts presented double reactivity HIV-1/HIV-2 in all the tests suggesting double infection. No prostitutes or homo/bisexual males were identified with positive serology for HIV-2. Cross-reactivity between HIV-1 and HIV-2 was more frequently detected in WB than in EID. Greater discordance was found in the results obtained by EIA, WB, and EID in the West Africans than in the analysis of the samples of native subjects.
Conclusions: This study demonstrates that, for the time being, HIV-2 infection in Spain is rare although from among immigrants from endemic areas subjects with behavior to risk of transmission to the autochthonous population have been identified. The use of techniques designed with synthetic peptides may be of use to discriminate HIV-1 and HIV-2 infection in positive samples by enzymatic immunoanalysis (EIA) and Western blot which use a viral lysate as antigenic material.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Equine Infectious Anemia Virus Cellular Partners Along the Viral Cycle.
Viruses
December 2024
ANSES Animal Health Laboratory, PhEED Unit, 14430 Goustranville, France.
Equine infectious anemia virus (EIAV) is the simplest described within the family, related to the human immunodeficiency viruses (HIV-1 and HIV-2). There is an important interplay between host cells and viruses. Viruses need to hijack cellular proteins for their viral cycle completion and some cellular proteins are antiviral agents interfering with viral replication.
View Article and Find Full Text PDFInterplay between the cyclophilin homology domain of RANBP2 and MX2 regulates HIV-1 capsid dependencies on nucleoporins.
mBio
January 2025
Department of Pediatrics, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Unlabelled: Interlinked interactions between the viral capsid (CA), nucleoporins (Nups), and the antiviral protein myxovirus resistance 2 (MX2/MXB) influence human immunodeficiency virus 1 (HIV-1) nuclear entry and the outcome of infection. Although RANBP2/NUP358 has been repeatedly identified as a critical player in HIV-1 nuclear import and MX2 activity, the mechanism by which RANBP2 facilitates HIV-1 infection is not well understood. To explore the interactions between MX2, the viral CA, and RANBP2, we utilized CRISPR-Cas9 to generate cell lines expressing RANBP2 from its endogenous locus but lacking the C-terminal cyclophilin (Cyp) homology domain and found that both HIV-1 and HIV-2 infections were reduced significantly in RANBP2 cells.
View Article and Find Full Text PDFRecent Advances in Design, Synthesis, and Biological Activity Studies of 1,3-Selenazoles.
Biomolecules
December 2024
A. E. Favorsky Irkutsk Institute of Chemistry, Siberian Branch of the Russian Academy of Sciences, 1 Favorsky Str., Irkutsk 664033, Russia.
The review examines recent advances in the design and synthesis of 1,3-selenazole derivatives since 2000. Various synthetic approaches to 1,3-selenazoles and reaction conditions are discussed. The beneficial properties of 1,3-selenazoles, especially their biological activity, are emphasized.
View Article and Find Full Text PDFExtra-Cavitary Primary Effusion Lymphoma in a Patient Co-infected With HIV-1 and HIV-2: A Case Review.
Cureus
December 2024
Infectious Diseases, Hospital Garcia de Orta, Lisbon, PRT.
Extra-cavitary primary effusion lymphoma (PEL), often associated with human herpes virus 8 (HHV8) infection, represents a rare and aggressive form of non-Hodgkin lymphoma, which is predominantly found in individuals with severe immunosuppression. As an acquired immunodeficiency syndrome (AIDS)-associated lymphoma, PEL typically manifests in the context of advanced human immunodeficiency virus (HIV) infection, requiring tailored therapeutic approaches to manage both the lymphoma and underlying immunodeficiency. A 53-year-old male patient from Cape Verde presented with a three-day history of fever, night sweats, right iliac fossa pain, hematochezia, and an unintentional weight loss of five kilograms over the previous two months.
View Article and Find Full Text PDFNovel Dolutegravir and Lenacapavir Resistance Patterns in Human Immunodeficiency Virus Type 2 Infection: A Case Report.
Open Forum Infect Dis
January 2025
Viroscience Department, Erasmus MC, Rotterdam, The Netherlands.
Background: The treatment management of human immunodeficiency virus (HIV)-2 infection presents greater challenges compared to HIV-1 infection, primarily because of inherent resistance against non-nucleoside reverse transcriptase inhibitors. Integrase strand transfer inhibitors, particularly dolutegravir, have improved treatment outcomes for people with HIV-2. Lenacapavir, a novel and potent antiretroviral capsid inhibitor, offers additional therapeutic options.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!